Introduction
Drägerwerk, a leading company in the field of medical technology, has experienced impressive stock development this year. The stock price has significantly recovered and is approaching the levels reached during the pandemic. An important factor for this development could be the engagement in the defense business, which is considered a growing market.
Stock Price Development
- Current Price: The price of Drägerwerk’s stock was last around €57.80, with significant fluctuations in recent months. In May and June 2025, the price fluctuated between €47.50 and €59.80.
- 52-Week High: The stock was trading just below its 52-week high of €68.50, which it briefly reached in recent months.
- Performance: The stock has shown a strong performance of about 48.96% since the beginning of the year compared to the previous year.
Growth Forecasts and Analyst Opinions
- Analyst Target: The average forecast by analysts is €76.00, which provides further potential of about 11.8%.
- RSI (14 days): With an RSI of 15.4, the stock is considered to be strongly oversold, indicating a possible correction.
- Volatility: The annualized volatility is 20.81%, indicating high uncertainty in the market.
Defense Business and Future Developments
Drägerwerk is positioning itself in a fast-growing market segment, which could be of interest to investors. Developments in this area could influence the company’s future growth. Despite the positive forecasts, the question remains whether the company can maintain its position. The further course of the buyback program and the performance in the core medical technology business will be crucial.
Financial Figures
- Earnings per Share (EPS): An EPS of about €5.71 is expected for 2025.
- Dividend: The dividend for 2025 is estimated to be €1.83, which corresponds to a dividend yield of about 2.97%.
- P/E Ratio: The P/E ratio for 2025 is estimated to be 10.81.
In summary, Drägerwerk shows strong growth potential, particularly due to its positioning in the defense business. However, future development will depend on various factors, including the continuation of the buyback program and the performance in the core business.